These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37404676)

  • 1. Increased prevalence of Parkinson's disease in alkaptonuria.
    Ranganath L; Khedr M; Milan AM; Davison AS; Norman BP; Janssen MCH; Lock E; Bou-Gharios G; Gallagher JA
    JIMD Rep; 2023 Jul; 64(4):282-292. PubMed ID: 37404676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Griffin R; Psarelli EE; Cox TF; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA
    Mol Genet Metab; 2018 Sep; 125(1-2):127-134. PubMed ID: 30055994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA
    Metabolites; 2022 Aug; 12(8):. PubMed ID: 36005644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients.
    Ahmad MSZ; Ahmed M; Khedr M; Borgia A; Madden A; Ranganath LR; Kaye S
    JIMD Rep; 2022 Jul; 63(4):351-360. PubMed ID: 35822094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
    Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
    J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria-An approach using statistical modelling.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Norman BP; Alsbou M; Imrich R; Gornall M; Sireau N; Gallagher JA; Jackson R
    JIMD Rep; 2022 Jan; 63(1):80-92. PubMed ID: 35028273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of low dose nitisinone in the management of alkaptonuria.
    Sloboda N; Wiedemann A; Merten M; Alqahtani A; Jeannesson E; Blum A; Henn-Ménétré S; Guéant JL; Renard E; Feillet F
    Mol Genet Metab; 2019 Jul; 127(3):184-190. PubMed ID: 31235217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients.
    Ranganath LR; Heseltine T; Khedr M; Fisher MF
    Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.
    Olsson B; Cox TF; Psarelli EE; Szamosi J; Hughes AT; Milan AM; Hall AK; Rovensky J; Ranganath LR
    JIMD Rep; 2015; 24():21-7. PubMed ID: 25772318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data on items of AKUSSI in Alkaptonuria collected over three years from the United Kingdom National Alkaptonuria Centre and the impact of nitisinone.
    Griffin R; Psarelli EE; Cox TF; Khedr M; Milan AM; Davison AS; Hughes AT; Usher JL; Taylor S; Loftus N; Daroszewska A; West E; Jones A; Briggs M; Fisher M; McCormick M; Judd S; Vinjamuri S; Sireau N; Dillon JP; Devine JM; Hughes G; Harrold J; Barton GJ; Jarvis JC; Gallagher JA; Ranganath LR
    Data Brief; 2018 Oct; 20():1620-1628. PubMed ID: 30263914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
    Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
    Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
    Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
    Norman BP; Davison AS; Hickton B; Ross GA; Milan AM; Hughes AT; Wilson PJM; Sutherland H; Hughes JH; Roberts NB; Bou-Gharios G; Gallagher JA; Ranganath LR
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.
    Khedr M; Judd S; Briggs MC; Hughes AT; Milan AM; Stewart RMK; Lock EA; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 40():31-37. PubMed ID: 28942493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.